Literature DB >> 12729912

VAMP/synaptobrevin cleavage by tetanus and botulinum neurotoxins is strongly enhanced by acidic liposomes.

Paola Caccin1, Ornella Rossetto, Michela Rigoni, Eric Johnson, Giampietro Schiavo, Cesare Montecucco.   

Abstract

Tetanus and botulinum neurotoxins (TeNT and BoNTs) block neuroexocytosis via specific cleavage and inactivation of SNARE proteins. Such activity is exerted by the N-terminal 50 kDa light chain (L) domain, which is a zinc-dependent endopeptidase. TeNT, BoNT/B, /D, /F and /G cleave vesicle associated membrane protein (VAMP), a protein of the neurotransmitter-containing small synaptic vesicles, at different single peptide bonds. Since the proteolytic activity of these metalloproteases is higher on native VAMP inserted in synaptic vesicles than on recombinant VAMP, we have investigated the influence of liposomes of different lipid composition on this activity. We found that the rate of VAMP cleavage with all neurotoxins tested here is strongly enhanced by negatively charged lipid mixtures. This effect is at least partially due to the binding of the metalloprotease to the lipid membranes, with electrostatic interactions playing an important role.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12729912     DOI: 10.1016/s0014-5793(03)00365-x

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  13 in total

Review 1.  Advances in intravesical therapy for urinary tract disorders.

Authors:  Pradeep Tyagi; Mahendra Kashyap; Harvey Hensley; Naoki Yoshimura
Journal:  Expert Opin Drug Deliv       Date:  2015-10-19       Impact factor: 6.648

2.  Synaptic vesicle chips to assay botulinum neurotoxins.

Authors:  Géraldine Ferracci; Raymond Miquelis; Shunji Kozaki; Michael Seagar; Christian Lévêque
Journal:  Biochem J       Date:  2005-11-01       Impact factor: 3.857

3.  A yeast assay probes the interaction between botulinum neurotoxin serotype B and its SNARE substrate.

Authors:  Hong Fang; Wentian Luo; Jim Henkel; Joseph Barbieri; Neil Green
Journal:  Proc Natl Acad Sci U S A       Date:  2006-04-24       Impact factor: 11.205

Review 4.  The blockade of the neurotransmitter release apparatus by botulinum neurotoxins.

Authors:  Sergio Pantano; Cesare Montecucco
Journal:  Cell Mol Life Sci       Date:  2013-06-11       Impact factor: 9.261

5.  Past, Present and Future of Chemodenervation with Botulinum Toxin in the Treatment of Overactive Bladder.

Authors:  Pradeep Tyagi; Mahendra Kashyap; Naoki Yoshimura; Michael Chancellor; Christopher J Chermansky
Journal:  J Urol       Date:  2016-11-18       Impact factor: 7.450

6.  State of the art in intravesical therapy for lower urinary tract symptoms.

Authors:  Jonathan Kaufman; Vikas Tyagi; Michele Anthony; Michael B Chancellor; Pradeep Tyagi
Journal:  Rev Urol       Date:  2010

7.  A common mechanism for the regulation of vesicular SNAREs on phospholipid membranes.

Authors:  Kuang Hu; Colin Rickman; Joe Carroll; Bazbek Davletov
Journal:  Biochem J       Date:  2004-02-01       Impact factor: 3.857

8.  Using fluorescent sensors to detect botulinum neurotoxin activity in vitro and in living cells.

Authors:  Min Dong; William H Tepp; Eric A Johnson; Edwin R Chapman
Journal:  Proc Natl Acad Sci U S A       Date:  2004-10-01       Impact factor: 11.205

9.  Lipid and cationic polymer based transduction of botulinum holotoxin, or toxin protease alone, extends the target cell range and improves the efficiency of intoxication.

Authors:  Chueh-Ling Kuo; George Oyler; Charles B Shoemaker
Journal:  Toxicon       Date:  2009-10-21       Impact factor: 3.033

10.  Sphingosine facilitates SNARE complex assembly and activates synaptic vesicle exocytosis.

Authors:  Frédéric Darios; Catherine Wasser; Anastasia Shakirzyanova; Artur Giniatullin; Kerry Goodman; Jose L Munoz-Bravo; Jesica Raingo; Jernej Jorgacevski; Marko Kreft; Robert Zorec; Juliana M Rosa; Luis Gandia; Luis M Gutiérrez; Thomas Binz; Rashid Giniatullin; Ege T Kavalali; Bazbek Davletov
Journal:  Neuron       Date:  2009-06-11       Impact factor: 17.173

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.